Kelsey M. Barter

Kelsey M. Barter

Auto-generated profile, based on publicly available information

Kelsey M. Barter

Division of Pediatric and Developmental Neurology, Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
BGBrian Mac Grory
Brian Mac Grory
MSMatthew Schrag
Matthew Schrag
SPSven Poli
Sven Poli
CBChantal J. Boisvert
Chantal J. Boisvert
Martin SpitzerMartin Spitzer
Martin Spitzer
WFWuwei Feng
Wuwei Feng

1 February 2024 in Neurology Clinical Practice
Verified
Journal Article
Closed access
KBKelsey M. Barter
Kelsey M. Barter
CFCatherine Fuchs
Catherine Fuchs
TGThomas B. Graham
Thomas B. Graham
LPLindsay M. Pagano
Lindsay M. Pagano
MVMcKenzie Vater
McKenzie Vater
A clinical practice guideline (CPG) was created to standardize evaluation and treatment for patients with suspected anti-methyl-d-aspartate receptor (NMDAR) autoimmune encephalitis (AE), the most common AE in children. The objective of this study was to evaluate the CPG effect on time to diagnosis, treatment, and hospital length of stay (LOS). Patients with an inpatient consult to pediatric rheumatology for AE during a 4-year period (period 2) after CPG implementation were identified. Data were extracted and compared with data over the preceding 4-year period (period 1). During period 1, fewer patients underwent diagnostic testing than during period 2 (34 vs 80). Number of patients diagnosed with AE did not differ from period 1 to that from period 2 (NMDAR AE 9 vs 8; seronegative AE 4 vs 5). The average time to diagnostic evaluation with lumbar puncture decreased from 5.4 to 1.5 days (p = 0.0082), and time to treatment decreased from 7.6 to 3.9 days (p = 0.018). LOS showed a trend toward improvement (40.4-29.2 days (p = 0.23)). Creation of a CPG for patients with suspected AE was associated with an improved time to diagnostic evaluation and treatment. With the CPG, more patients underwent AE testing, though total diagnoses remained the same.

10 September 2024 in Pediatric Neurology
Verified
Journal Article
Closed access
KBKelsey Barter
Kelsey Barter
SSSiefaddeen Sharayah
Siefaddeen Sharayah
UMUrmi Mange
Urmi Mange
CGCristina M. Gaudioso
Cristina M. Gaudioso
NSNatalie Schanzer
Natalie Schanzer
SMSoe Mar
Soe Mar

25 November 2025 in Pediatric Neurology
Verified
Journal Article
Open access
CGClaudia Gambrah-Lyles
Claudia Gambrah-Lyles
KBKelsey Barter
Kelsey Barter
MDMichelle Doering
Michelle Doering
SMSoe Mar
Soe Mar
Pediatric-onset multiple sclerosis (POMS) is a chronic, immune-mediated disease of the central nervous system that accounts for up to 10% of all multiple sclerosis cases. Compared to adult-onset multiple sclerosis, POMS follows a more aggressive course with frequent relapses and earlier disability milestones. A structured transition-to-adult care is critical for maintaining long-term health. While transition-to-adult care has been studied in children with other chronic conditions, there are few transition studies in POMS, leaving youth with POMS vulnerable to poor outcomes. This scoping review aims to synthesize the existing literature on transition-to-adult care in POMS within the broader context of chronic pediatric illness and identify gaps to guide future research. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided scoping review in February 2025 across PubMed, Scopus, Ovid Medline, Web of Science, and Embase databases, using English-language filters. Two independent reviewers screened each record at the title/abstract and full-text stages. Of 96 articles meeting inclusion criteria, 12 specifically addressed POMS. A range of strategies for transition-to-adult care have been studied in other chronic pediatric conditions, but findings are limited by inconsistent definitions and lack of standardized outcome measures. The POMS-specific literature reveals specific barriers, such as cognitive impairment, fluctuating symptoms, and psychosocial complexity. As a whole, there is limited evidence on the efficacy of targeted interventions to support successful transition-to-adult care. The evidence for beneficial interventions and strategies in transition-to-adult care in POMS is limited in quantity and scope. Targeted research is needed to develop and evaluate tailored strategies informed by general care plan frameworks and disease-specific needs.

27 October 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
KBKelsey Mackenzie Barter
Kelsey Mackenzie Barter
ATAye Thant
Aye Thant
MPMonye Pitt
Monye Pitt
VTVishnuvardhan Thotakura
Vishnuvardhan Thotakura
AWAnne M. Wagner
Anne M. Wagner
SMSoe Mar
Soe Mar
Multiple sclerosis (MS) is a demyelinating disease of the CNS with an estimated incidence of 0.05–2.85 per 100,000 children. One subtype, tumefactive MS, is particularly rare and difficult to diagn...